Form 4: ANI Pharmaceuticals SVP, Chief HR Officer Reports Changes in Beneficial Ownership

Krista Davis, SVP, Chief HR Officer of ANI Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Summary

• Krista Davis, the SVP, Chief HR Officer of ANI Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 12, 2025, Davis acquired 13,057 shares of common stock through a restricted stock award and 8,704 shares through performance stock units, both at a price of $0.
• On February 14, 2025, 1,196 shares were disposed of at $58.92 for tax purposes related to the vesting of restricted stock.
• Following these transactions, Davis beneficially owns 69,624 shares of ANI Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Future Outlook

The restricted stock award will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 12, 2025. The performance stock units will vest over the applicable performance period based on the achievement of the provided performance targets.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the actions of company executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant.

Key Dates

Keywords

Form 4, Beneficial Ownership, ANI Pharmaceuticals, ANIP, Krista Davis, Restricted Stock, Performance Stock Units, Tax Withholding